HCM HUTCHMED (China) Limited: Rasio Kapitalisasi Pasar marang Nilai Buku

Simbol resmi perusahaan Hutchison MediPharma (HCM)

Developing new cancer drugs requires colossal research expenditures and navigating stringent FDA oversight. The price action of HUTCHMED (China) Limited (HCM) at the 1.84 level illustrates the trajectory of a company that delegates manufacturing and marketing to external contractors to concentrate on therapy. Meanwhile, the Hong Kong-based business is overcoming the complexities of the US-China trade conflict by establishing sophisticated legal structures for expansion.

HUTCHMED Corp (HCM): Rasio Kapitalisasi marang Nilai Buku saka 04.07.2022 nganti 29.10.2026

HCM (Hutchison MediPharma): rincian analitis lan laporan miturut indikator

- rega lan prakiraan konsensus rega:
Rega saham HUTCHMED (China) Limited|HCM - Rentang target analis
- data kapitalisasi pasar:
Kapitalisasi pasar HUTCHMED Ltd|HCM - Total Nilai Perusahaan
- data kapitalisasi buku:
Aset Bersih saben Siji Saham HUTCHMED|HCM - Kapitalisasi Akuntansi|Rasio Kapitalisasi Pasar marang Nilai Buku hutch-med.com|HCM - Aset Perusahaan
- data utang lan likuiditas:
Utang marang Ekuitas HUTCHMED (China) Limited|HCM - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang modal HUTCHMED Ltd|HCM - Gunggung utang perusahaan|Rasio utang marang kapitalisasi buku HUTCHMED Ltd|HCM - Utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan HUTCHMED
Pambiji fundamental:HUTCHMED (China) Limited
Produk asli Hutchison MediPharma

To assess the credit quality of HUTCHMED (China) Limited (HCM), the analyst compares the business's market value with its net assets, which allows for the determination of the growth premium through the company's current P/B ratio. HUTCHMED (China) Limited (HCM) strategic alliances in oncology and clinical trial synergies create intangible value that often exceeds book value, reflecting the commercialization potential of new drugs.

Pesaing utama

Rasio Kapitalisasi Pasar marang Nilai Buku INCY (Incyte Corporation)|nuvationbio.com (NUVB) - Rasio Nilai Pasar marang Ekuitas|Rasio Kapitalisasi Pasar marang Nilai Buku DAWN (Day One Biopharmaceuticals)|Koefisien Nilai Pasar marang Nilai Buku MNPR|Rasio Nilai Pasar marang Nilai Buku Inhibrx Biosciences Inc INBX|Rasio Kapitalisasi marang Nilai Buku i-mabbiopharma.com (IMAB)|FENC: Rasio Kapitalisasi Pasar marang Nilai Buku|Heron - Koefisien Nilai Pasar marang Nilai Buku|Rasio Nilai Pasar marang Nilai Buku Nuvectis Pharma (NVCT)|CHRS - Nilai Pasar marang Nilai Buku|CRBP: Rasio Kapitalisasi Pasar marang Nilai Buku|CRDF (Cardiff Oncology) - Rasio Kapitalisasi Pasar marang Nilai Buku|Rasio Nilai Pasar marang Nilai Buku BeyondSpring Inc.|Rasio Nilai Pasar marang Nilai Buku BioAtla Corp (BCAB)|Lixte Biotechnology Holdings, Inc. (LIXT) - Rasio Kapitalisasi marang Aset Bersih|Nilai Pasar marang Nilai Buku CTXR (citiuspharma.com)|CLRB: Rasio Nilai Pasar marang Nilai Buku|BioLineRx Corporation - Koefisien Nilai Pasar marang Nilai Buku|Can-Fite BioPharma (CANF) - Rasio Nilai Pasar marang Nilai Buku|APRE - Rasio Kapitalisasi marang Nilai Buku|KZIA (kaziatherapeutics.com) - Rasio Kapitalisasi Pasar marang Nilai Buku|SLXN (Silexion Therapeutics) - Rasio Kapitalisasi marang Aset Bersih|Rasio Nilai Pasar marang Nilai Buku NCNA (NuCana PLC)|Koefisien Nilai Pasar marang Nilai Buku CMRX|Rasio Nilai Pasar marang Nilai Buku Cyclacel Pharmaceuticals (CYCC)|Rasio Nilai Pasar marang Nilai Buku GTHX (g1therapeutics.com)|KRON: Rasio Nilai Pasar marang Nilai Buku|Koefisien Nilai Pasar marang Nilai Buku Kintara Therapeutics Inc KTRA|Rasio Kapitalisasi Pasar marang Nilai Buku ONCT|Portage Biotech Corp (PRTG) - Rasio Nilai Pasar marang Ekuitas